Market Update (NYSE:PFE): Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older

[at noodls] – NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar … Read more on . . . → Read More: Market Update (NYSE:PFE): Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older Similar Articles: Stock Update (NYSE:PFE): Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China Market Update (NYSE:PFE): Pfizer Enters Into Agreement to Acquire Baxter’s Portfolio of Marketed Vaccines Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine